A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study

NCT03067285 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: ELV/COBI/FTC/TAF
DRUG: DTG/3TC/ABC + ELV/COBI/FTC/TAF

Sponsor

Fundacion SEIMC-GESIDA